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Abstract 
Goal 
The goal of this Capstone project was to provide meaningful Continuing Education (CE) to 
clinicians in the Midwest to reduce perceived challenges to safely treating patients co-
prescribed opioid analgesics and benzodiazepines 
Objectives 
Using continuing education, increase clinician knowledge of effective alternative non-opioid 
and non-benzodiazepine therapies for chronic conditions while increasing clinician comfort in 
tapering patients off opioid analgesics and benzodiazepines 
Methods 
A one-hour CE presentation was prepared with the assistance of the Nebraska Department of 
Health and Human Services (NeDHHS) and broadcast to clinicians in the Midwest through a live 
webinar in coordination with the Great Plains Quality Innovation Network (GPQIN) and the 
Nebraska Medical Association (NMA). Clinicians registering for the webinar included physicians, 
mid-level providers such as physician assistants and nurse practitioners, pharmacists, and 
nurses. In the process of registering for the webinar, clinicians were required to answer five 
questions to assess their perceived knowledge of effective alternative non-opioid and non-
benzodiazepine therapies and their comfort with tapering patients off opioid analgesics and 
benzodiazepines. After the webinar, providers were required to complete a post-assessment 
survey of identical questions to obtain their CE credit. These questions were arranged on a 5-
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point Likert scale describing their level of agreement with the statements posed. Post-webinar 
responses were compared to the pre-webinar responses to examine the effect of the CE 
presentation on provider knowledge and comfort in treating patients prescribed both opioids 
and benzodiazepines. The Wilcoxon signed-rank test was used to compare the pre- and post-
webinar responses to determine if the CE presentation was associated with a difference in self-
reported knowledge and comfort in guideline recommended practices.  
Project Impact 
This study demonstrated that continuing education was associated with a statistically 
significant increase in self-reported clinician knowledge of effective alternative non-opioid and 
non-benzodiazepine therapies for chronic conditions while also increasing self-reported 
clinician comfort in tapering patients off opioid analgesics and benzodiazepines. State health 
departments should promote the use of CE in reducing perceived challenges to safely treating 
patients co-prescribed opioid analgesics and benzodiazepines in their efforts to decrease the 
incidence of opioid-related overdose deaths.  
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Introduction 
The rate of drug overdose death in the United States increased significantly from 6 per 
100,000 population in 1999 to 13.8 per 100,000 in 2013 (Paulozzi, 2015). This increase is largely 
attributed to drug overdose deaths involving prescription opioid analgesics (Paulozzi, 2015). 
Commonly prescribed for the treatment of moderate to severe pain, opioid analgesics can 
cause serious adverse events such as potentially fatal respiratory depression at higher doses 
(Dowell, 2016). The rate of opioid-related overdose deaths nearly quadrupled from 1.4 per 
100,000 population in 1999 to 5.4 per 100,000 in 2011 (Chen, 2014). More than 165,000 people 
died of opioid-related overdose between 1999 to 2014 (Dowell, 2016). In 2013 alone, about 1.9 
million people either abused or were dependent on opioid therapies (Dowell, 2016). On 
average, 115 Americans die from an opioid-related overdose every day (Hedegaard, 2017). 
Benzodiazepines, a class of sedatives used for the treatment of anxiety and other 
disorders, can increase the risk of overdose when used in combination with opioid therapies. 
An increase in opioid overdoses involving benzodiazepines has been associated with a portion 
of the increased rate of drug overdoses observed over the past decade (Chen, 2014). In 2011, 
benzodiazepines were involved in 31% of opioid-related overdose deaths, up from 13% of 
opioid-related deaths in 1999 (Chen, 2014). The rate of emergency room visits involving both 
opioid therapies and benzodiazepines increased from 11 per 100,000 population in 2004 to 
34.2 per 100,000 in 2011 (Jones, 2015). During this same period, drug overdose deaths 
involving the combination of these therapies increased from 0.6 per 100,000 population to 1.7 
per 100,000 (Jones, 2015). Recent statewide studies have found benzodiazepines to be involved 
in 68.4% of prescription opioid-related deaths in New York City, while the rate of overdose 
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death in North Carolina was ten times higher for patients co-prescribed opioids and 
benzodiazepines versus opioids alone (Sgarlato, 2015; Dasgupta, 2016). In 2016, the U.S. Food 
and Drug Administration (FDA) required updated labeling of benzodiazepines to warn health 
care providers and patients about the serious risks associated with their use when combined 
with opioids therapies (FDA, 2016).  
In addition to being at an increased risk of overdose and death, patients prescribed 
benzodiazepines in combination with opioids have been found to exhibit poorer outcomes in 
the treatment of chronic pain compared to patients receiving only opioids. Specifically, patients 
taking opioids for chronic pain received opioids for a longer duration if they were also 
prescribed benzodiazepines (Jones, 2015). Additionally, patients who received both opioids and 
benzodiazepines were more likely to have a history of substance use disorder and depression 
(Jones, 2015). Patients receiving low doses of opioid therapies are still at an increased risk when 
taken concurrently with benzodiazepines. Among Washington Medicaid recipients, patients 
receiving doses as low as 1-19 milligram equivalents of morphine per day in combination with 
sedatives, such as benzodiazepines, had 5.6 times the risk of opioid overdose compared to 
those not receiving sedatives (Garg, 2017). These observed increases in morbidity and mortality 
suggest the need to create initiatives aimed at decreasing the concurrent use of opioids and 
benzodiazepines. Studies have shown the risk of emergency room visits and inpatient 
admissions related to opioid use could be reduced by an estimated 15% by eliminating the 
combined use of these two therapies (Sun, 2017).   
In 2016, the Center for Disease Control and Prevention (CDC) published guidelines for 
prescribing opioids for chronic pain in the Journal of the American Medical Association (Dowell, 
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2016). These guidelines list non-opioid therapies as the preferred treatment of chronic pain and 
recommend opioids be used only when the benefits for pain and function are expected to 
outweigh their risks (Dowell, 2016). These guidelines explicitly state to avoid the concomitant 
use of opioids and benzodiazepines whenever possible (Dowell, 2016). Recommendations to 
arrange evidence-based treatment such as medication assisted treatment (MAT) for patients 
with opioid use disorder are also provided (Dowell, 2016). Several states have also developed 
their own guidelines and enacted programs in an attempt to reduce opioid-related overdose 
deaths. In 2011, more than 70 local healthcare professionals in Oregon formed the Oregon Pain 
Guidance (OPG) group. The OPG group, comprised of nurses, prescribers, pharmacists, and 
behavioral health clinicians, meets monthly to update and encourage the use of their own pain 
guidance document. The goal of the Oregon Pain Guidance Document is to reduce the 
morbidity and mortality associated with the misuse of opioids while increasing focus on non-
opioid treatments (OPG, 2014). In Washington, an advisory group of state academic leaders, 
pain experts, and clinicians developed the Washington State Agency Medical Directors’ Group’s 
(AMDG) Interagency Opioid Guideline in 2007. The guideline is currently on its third edition 
after updates in 2010 and most recently in 2015. This guideline provides a “balanced approach 
to pain management that includes recommendations for using opioids when appropriate, such 
as with acute injuries and flare ups, for postoperative pain management, and during pain 
procedures; and recommending multimodal therapies in general for all chronic pain patients” 
(AMDG, 2015). Since inception of the AMDG guideline and other statewide efforts in 
Washington, the rate of prescription opioid-related deaths decreased by 29% from 2008 and 
2013, with hospitalizations for prescription opioid overdose also declining by 29% between 
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2011 and 2013 (AMDG, 2015). Both the Oregon Pain Guidance Document and the AMDG 
Interagency Guideline caution against the co-prescribing of opioids and benzodiazepines while 
offering specific guidance on safely tapering these therapies when appropriate.  
The Nebraska Department of Health and Human Services (NeDHHS) has worked with 
several stakeholders to promote safe opioid practices. The NeDHHS Division of Public Health, 
which is responsible for preventive and community health services, regulates and licenses 
health-related professions and occupations, among other responsibilities. In October of 2017, 
the NeDHHS published the Nebraska Pain Management Guidance Document in collaboration 
with an expert advisory task force, active providers, and state officials (NeDHHS, 2017). This 
document, which resembles the Oregon Pain Guidance Document, included several of the CDC 
recommendations for opioid therapies, along with several additional resources for treating 
patients who are receiving concurrent benzodiazepine and opioids (NeDHHS, 2017). The 
guideline recommends patients receiving opioids be screened for benzodiazepine use upon 
intake and to offer naloxone to all patients of high risk, such as those receiving concomitant 
benzodiazepines and opioids (NeDHHS, 2017). Specific regimens are listed to help taper 
patients off their benzodiazepine and/or opioid with specific tools and considerations provided 
(NeDHHS, 2017). Additionally, the guideline recommends that patients refusing to dose reduce 
their opioid and benzodiazepine should be referred to pain specialty care (NeDHHS, 2017).  
Despite a strong agreement with federal and state clinical practice guidelines, providers 
have reported several barriers contributing to continued co-prescribing of opioids and 
benzodiazepines (Hawkins, 2017). In a study surveying primary care and mental health 
prescribers, 40% of providers indicated that co-prescribing opioids and benzodiazepines 
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continues because patients appear stable on therapy and tapering is too difficult (Hawkins, 
2017). Other barriers listed include the difficulty of addressing patients who refuse to 
discontinue treatment (Hawkins, 2017). Furthermore, tapering patients off benzodiazepines is a 
difficult process. The traditional approach is to provide a slow dose reduction of 5% to 25% 
every 1 to 4 weeks until the benzodiazepine is discontinued (Ogbonna, 2017). During the taper 
process, patients may experience several withdrawal symptoms, such as dizziness, recurrence 
of severe anxiety, insomnia, and other bodily symptoms (Lader, 2016). If the patient’s 
benzodiazepine is immediately discontinued without a taper, they are at risk of experiencing 
life-threatening convulsions (Lader, 2016). Evidence to support non-pharmacologic and 
pharmacologic therapies to aid patients in tapering benzodiazepines is based on expert opinion 
and low-quality evidence (Baandrup, 2018). Tapering opioids is also a difficult process for 
patients and providers. Tapering opioids can take weeks to months, depending on the dose and 
duration of their opioid therapy. Patients may experience widespread opioid withdrawal 
symptoms and are at an increased risk for self-harm and suicide while tapering (Moss, 2019). 
Similar to tapering benzodiazepines, guidelines do not include evidence-based practices for 
opioid discontinuation, but rather provide best practices based on expert opinion (Berna, 
2015).  
A survey was distributed to Nebraska physicians in coordination with the Nebraska 
Medical Association in February 2019 to assess current challenges to treating patients 
prescribed opioid and benzodiazepines. There were 79 total physicians who responded to the 
survey, 43.6% of which identified their specialty as Family Medicine and 71.1% of which self-
identified as practicing in an urban setting (defined as a city of greater than 50,000 people). This 
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survey and its results are listed in Appendices A and B, respectively. Several respondents agreed 
that certain barriers contribute to patients remaining on concomitant opioids and 
benzodiazepines. A majority (63.3%) of respondents agreed or strongly agreed that patients 
appear stable on these medications with no adverse effects. An identical majority (63.3%) of 
respondents also agreed or strongly agreed that it is difficult to coordinate with other 
prescribers to taper therapies. However, only 26.6% of respondents agreed or strongly agreed 
that the benefits of concomitant opioids and benzodiazepines appear to exceed the risks. 
Several respondents indicated there are limited alternative treatments for anxiety and pain and 
a lack of practical methods for tapering opioids and benzodiazepines. In free response sections 
of the survey, respondents stated they frequently meet resistance from patients unwilling to 
taper, withdrawal symptoms are a significant barrier to tapering, and patients often dropout of 
care during the taper process and seek opioids or benzodiazepines from other providers. 
Respondents noted they would like information on discussing the topic of tapering with 
patients and would like to know of additional evidence-based non-opioid therapies for the 
treatment of pain and non-benzodiazepine therapies for the treatment of mental health 
disorders such as anxiety and insomnia.  
Given the increased involvement of benzodiazepines in opioid-related deaths and the 
reported challenges contributing to their continued concurrent use, targeted education to 
clinicians on best practices in tapering opioids and benzodiazepines and guideline 
recommended treatment alternatives for chronic pain and mental health disorders is necessary. 
This study seeks to determine if a one-hour CE presentation, prepared in coordination with the 
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NeDHHS, is associated with a difference in self-reported knowledge and comfort in guideline 
recommended practices. 
Methods 
Research Question:  
Can one hour of CE provide meaningful education to clinicians in the Midwest United 
States to reduce the perceived challenges of safely treating patients prescribed opioids and 
benzodiazepines? 
Application of Theoretical Models 
Theories used to create an effective CE presentation will be based on the Elaboration 
Likelihood Model (ELM). This theory of persuasive communication assumes that people differ in 
their abilities and motivation for thoughtful information processing and aims to change 
attitudes with logic, reasoning, and effective communication (Bartholomew, 2016). In this 
model, successful communication is key to gain the attention of providers and convey the 
message being presented (Bartholomew, 2016).  The method of active processing was utilized 
with survey questions before and after the live webinar (Bartholomew, 2016). Strong 
arguments were created for the avoidance of concomitant opioid and benzodiazepine 
prescribing. To create a strong argument, the presentation repeatedly framed co-prescribing 
opioids and benzodiazepines as an undesirable outcome to avoid while conveying a causal 
relationship between co-prescribing and increased morbidity and mortality (Bartholomew, 
2016). Recommendations were applicable and feasible to current practice, relevant to patient 
safety, and unique from previous arguments (Bartholomew, 2016). An additional method to 
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improve information processing was to create a recorded, on-demand presentation posted on 
the NMA website that will allow self-pacing.  
Study Design 
A one-hour CE presentation prepared with the assistance of the NeDHHS was broadcast to 
clinicians in the Midwest through a live webinar in coordination with the Great Plains Quality 
Innovation Network (GPQIN) and the Nebraska Medical Association (NMA). In the process of 
registering for the webinar, clinicians were required to answer five pre-webinar questions to 
assess their perceived knowledge of effective alternative non-opioid and non-benzodiazepine 
therapies and their comfort with tapering patients off opioid analgesics and benzodiazepines. 
The pre-webinar questions also surveyed if prescribers utilized assessment tools and 
Prescription Drug Monitoring Program (PDMP) data when prescribing opioids or 
benzodiazepines for long term use. The PowerPoint slides used for this live webinar event can 
be found in Appendix C. The objectives of the live webinar were the following:  
1. Discuss the morbidity and mortality associated with concomitant opioid and 
benzodiazepine therapy 
2. Summarize the evidence to support therapies for the treatment of anxiety, insomnia, 
and pain 
3. Evaluate strategies for tapering opioid analgesics and benzodiazepines 
4. Discuss strategies to engage patients in difficult conversations and outline appropriate 
patient selection for referral to specialty care 
12 
 
After the webinar, providers were required to complete a post-webinar survey of questions 
identical to the pre-webinar survey to obtain their CE credit. The questions included in the pre- 
and post-webinar surveys were arranged on a 5-point Likert scale describing their level of 
agreement with the statements posed. These questions are listed below in Figure 1.  
Figure 1: Pre- and Post-Webinar Survey Questions 
Please select the option that best describes your level of agreement with the statement 
1. I am knowledgeable of effective non-opioid therapies to treat chronic pain. 
       a. Strongly Disagree     b. Disagree      c. Neither Disagree or Agree    d. Agree   e. Strongly Agree 
2. I am knowledgeable of effective non-benzodiazepine therapies to treat anxiety disorders.  
       a. Strongly Disagree     b. Disagree      c. Neither Disagree or Agree    d. Agree   e. Strongly Agree 
3. I feel comfortable tapering my patients off opioid therapies  
       a. Strongly Disagree     b. Disagree      c. Neither Disagree or Agree    d. Agree   e. Strongly Agree 
4. I feel comfortable tapering my patients off benzodiazepine therapies  
       a. Strongly Disagree     b. Disagree      c. Neither Disagree or Agree    d. Agree   e. Strongly Agree 
5. I utilize assessment tools and Prescription Drug Monitoring Program (PDMP) data to evaluate the 
risk of medication misuse when prescribing opioids or benzodiazepines for long term use.  
       a. Strongly Disagree     b. Disagree      c. Neither Disagree or Agree    d. Agree   e. Strongly Agree 
In the post-webinar survey, the format of question 5 was changed to the following:  
5. Going forward, I will utilize assessment tools and Prescription Drug Monitoring Program (PDMP) 
data to evaluate the risk of medication misuse when prescribing opioids or benzodiazepines for 
long term use.  
       a. Strongly Disagree     b. Disagree      c. Neither Disagree or Agree    d. Agree   e. Strongly Agree 
 
Study Population and sample size 
The target population were Midwest clinicians including physicians, mid-level 
prescribers such as physician assistants and nurse practitioners, pharmacists, and nurses. A 
total of 131 clinicians registered for the live webinar, including clinicians in states outside of the 
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Midwest (e.g., Rhode Island, New Jersey, etc.). A total of 31 clinicians completed the post-
webinar assessment per protocol and were included in the study sample and statistical analysis. 
See Table 1 for baseline characteristics of the study sample and Figure 2 for inclusion of 
clinicians in the study sample.   
Data source and collection methods 
Up to one month prior to viewing the live CE webinar, clinicians were required to submit 
responses to pre-webinar survey questions during the registration process. These responses 
were submitted through a third-party company and delivered to the GPQIN within 7 days 
following the live webinar. Clinicians were then required to provide responses to post-webinar 
survey questions after the event in order to attain their CE credit (see Figure 1 for pre- and 
post-webinar survey questions). These post-webinar responses were submitted directly to the 
GPQIN through the application SurveyMonkey.  
Statistical methods 
Post-webinar responses were compared to pre-webinar responses to examine the effect 
of the CE presentation on provider knowledge and comfort in treating patients prescribed both 
opioids and benzodiazepines. As detailed in Figure 1, responses were provided on a 5-point 
Likert scale from Strongly Disagree to Strongly Agree. For the purpose of this study, responses 
were changed to a scale of 1 (Strongly Disagree) to 5 (Strongly Agree). Due to the ordinal nature 
of Likert scale data collected among paired groups, the nonparametric Wilcoxon signed-rank 
test (α = 0.05) using XLSTAT software in Microsoft Excel was used to compare the pre- and post-
webinar responses to determine if the CE presentation was associated with a statistically 
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significant difference in responses. A secondary analysis was completed among prescribers only 
(i.e., physicians, nurse practitioners, and physician assistants) using the same statistical 
methods.  
Results 
A total of 131 clinicians registered for the CE webinar and submitted pre-webinar survey 
questions. Of those who registered, only 59 clinicians were documented as attending the online 
live CE webinar, and 37 clinicians at least partially completed post-webinar survey questions. 
Only 31 clinicians fully completed the post-webinar survey questions and included the 
information necessary to link their post-webinar responses to their pre-webinar responses. 
These 31 clinicians were included in the per protocol study sample and statistical analysis. See 
Figure 2 for the Flow Diagram of study sample inclusion.  
Figure 2. Flow Diagram of Respondents Included in Study Sample: 
 
 
 
 
 
 
 
 
Clinicians who registered and completed pre-webinar survey questions 
n = 131 
Clinicians who attended online live webinar 
n = 59 
Clinicians who completed post-webinar survey questions for CE credit 
n = 37 
Clinicians who submitted all required information in their post-webinar responses 
to link their pre-webinar responses for comparison 
n = 31 
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Demographic data of respondents in the per protocol study sample is listed in Table 1. 
There were 12 prescribers (i.e., physicians, physician assistants, nurse practitioner), 5 
pharmacists, 12 nurses, and 2 other clinicians included in the study sample. While the majority 
(74.2%) of respondents practiced in Nebraska, the study sample included respondents from 
several other states in and outside of the Midwest. A majority (64.5%) of respondents practiced 
in rural areas, defined as a city less than 50,000 total population as of the 2010 census while 
not being part of a greater metropolitan area. 
Table 1. Demographics of Respondents in Study Sample 
Characteristic N n (%) 
Clinician Type   
   Physician 5 16.1 
   Physician Assistant 4 12.9 
   Nurse Practitioner 3 9.7 
   Pharmacist 5 16.1 
   Nursing 12 38.7 
   Other 2 6.5 
State   
   Illinois 1 3.2 
   Kansas 2 6.5 
   Nebraska 23 74.2 
   New Jersey 1 3.2 
   Oklahoma 1 3.2 
   Rhode Island 2 6.5 
   South Dakota 1 3.2 
Urban or Rural*   
   Urban 11 35.5 
   Rural 20 64.5 
* Rural defined as city less than 50,000 population as of 2010 census and not part of a greater 
metropolitan area 
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Several respondents submitted higher scores in their post-webinar responses in 
comparison to their pre-webinar responses. The mean pre- and post-webinar responses in the 
study sample, along with the associated p-values, are listed in Table 2. There was an increase in 
the mean post-webinar response scores when compared to the mean pre-webinar responses 
for all five survey questions. The associated increase in survey response scores between pre- 
and post-survey questions were all statistically significant (p-value < 0.05). A complete table of 
the responses submitted, along with associated demographic information, can be found in 
Appendix D.  
Table 2. Difference in Pre- and Post-Webinar Responses in Study Sample (n = 31) 
 Question 
Pre-
Webinar 
Mean 
Post-
Webinar 
Mean 
p-
value 
1 
I am knowledgeable of effective non-
opioid therapies to treat chronic pain.  
3.97 4.29 0.025* 
2 
I am knowledgeable of effective non-
benzodiazepine therapies to treat anxiety 
disorders.    
3.55 4.26 0.001* 
3 
I feel comfortable tapering my patients 
off opioid therapies.   
3.45 4.10 0.016* 
4 
I feel comfortable tapering my patients 
off benzodiazepine therapies.  
3.42 4.07 0.011* 
5 
[Going forward,] I [will] utilize assessment 
tools and Prescription Drug Monitoring 
Program (PDMP) data to evaluate the risk 
of medication misuse when prescribing 
opioids or benzodiazepines for long term 
use.    
3.55 4.39 0.002* 
*Statistically significant difference in question response with alpha = 0.05 
 
 Not all questions included in the pre- and post-webinar surveys apply to clinicians that 
do not regularly prescribe therapies. For instance, questioning a nurse or pharmacist if they feel 
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comfortable tapering opioids and benzodiazepines may not be appropriate. Therefore, a 
secondary analysis was performed among the clinicians in the study sample who regularly 
prescribe medications (i.e., physicians, physician assistants, nurse practitioners). There were 12 
total prescribers included in this analysis. The mean pre- and post-webinar responses in this 
study sample, along with the associated p-values, are listed in Table 3. While several prescribers 
listed higher scores in the post-webinar responses compared to the pre-webinar responses, this 
increase was not found to be statistically significant for 4 out of 5 of the questions. There was a 
statistically significant increase in response scores for the survey question on perceived 
knowledge of effective non-benzodiazepine therapies for the treatment of anxiety disorders in 
this secondary analysis.  
Table 3. Difference in Pre- and Post-Webinar Responses Among Prescribers in Study Sample 
(n = 12) 
Question 
Number 
Question 
Pre-
Webinar 
Mean 
Post-
Webinar 
Mean 
p-
value 
1 
I am knowledgeable of effective non-
opioid therapies to treat chronic pain.   
4.17 4.33 0.414 
2 
I am knowledgeable of effective non-
benzodiazepine therapies to treat anxiety 
disorders.    
3.33 4.33 0.018* 
3 
I feel comfortable tapering my patients 
off opioid therapies.   
3.83 4.25 0.265 
4 
I feel comfortable tapering my patients 
off benzodiazepine therapies.  
3.83 4.17 0.331 
5 
[Going forward,] I [will] utilize assessment 
tools and Prescription Drug Monitoring 
Program (PDMP) data to evaluate the risk 
of medication misuse when prescribing 
opioids or benzodiazepines for long term 
use.    
3.58 4.33 0.133 
*Statistically significant difference in question response with alpha = 0.05 
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Discussion 
 In previous needs assessments, clinicians have indicated that a lack of effective non-
opioid and non-benzodiazepine therapies have contributed to patients remaining on co-
prescribed opioids and benzodiazepines. Clinicians have also previously indicated that there is a 
lack of guidance on appropriate and evidenced-based tapering methods for patients prescribed 
these therapies. This CE webinar was constructed based on the results of these needs 
assessments to provide clinicians with the information necessary to improve their knowledge of 
alternative therapies used to treat pain and mental health disorders while providing tools and 
recommended practices to assist in tapering opioids and benzodiazepines. This study 
demonstrates that a one-hour CE webinar was associated with a statistically significant 
difference among clinicians in self-reported comfort in tapering patients off opioids and 
benzodiazepines and knowledge in treating patients with alternative therapies.  
 In the secondary analysis, only prescriber responses (n=12) were compared to detect if 
there was a difference in pre- and post-webinar responses. While we found a statistically 
significant difference in reported knowledge of effective non-benzodiazepine therapies to treat 
anxiety disorders and a trend of increased mean survey responses for the other survey 
questions, we did not find statistically significant differences in 4 out of 5 of the survey 
questions. This may be due to higher mean response scores in the pre-webinar responses, as 
the prescriber group may have a higher baseline knowledge of these topics when compared to 
the average clinician in the non-prescribing group. It may also be due to the decrease in sample 
size, making it difficult to detect a statistically significant difference given the relatively small 
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effect size. Future analyses of the effectiveness of CE presentations should seek to include a 
higher number of prescribers to increase study power.  
 In the current opioid epidemic, clinicians have faced increased scrutiny over their opioid 
and benzodiazepine prescribing habits. Several states have mandated certain prescribing 
practices when treating patients with opioid analgesics. Several health plans and pharmacy 
benefit managers have also enacted clinical and drug utilization review (DUR) programs limiting 
opioid prescribing. Physicians have voiced their frustration over mandated forced opioid 
tapering due to limits imposed by these state regulations and clinical programs (Darnall, 2019). 
While the benefits of chronic opioids and benzodiazepines often do not outweigh their risks, 
tapering these therapies can be associated with risks of their own (Moss, 2019). Education to 
clinicians in the form of CE may offer a solution to state agencies searching for programs aimed 
at improving prescribing habits without mandating potentially dangerous prescribing practices.   
 As discussed earlier, there is substantial data to suggest that the increased use of 
benzodiazepines in combination with opioids is associated with a portion of the increase in 
opioid related deaths. Efforts to decrease opioid overdose deaths should continue to focus on 
promoting non-benzodiazepine therapies and non-pharmacologic therapies for the treatment 
of mental health disorders. Future studies should investigate the benefit in providing clinicians 
with CE presentations that include tools to engage patients in the difficult discussion of 
tapering. While these discussions are critical to tapering efficacy, and while the CE presentation 
included recommendations for engaging patients in these difficult discussions, this study did 
not directly measure if providers found this type of information helpful. As future clinical trials 
are completed on evidenced-based treatments to taper patients off opioids and 
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benzodiazepines, these protocols should be shared with clinicians in the form of CE as current 
guidelines for tapering these therapies are largely based on expert opinion. State health 
departments should continue to promote the use of assessment tools and PDMP’s as these 
tools and programs continue to be underutilized in practice based on needs assessment 
responses and the pre-webinar responses in this study.  
 In the process of creating the CE presentation for this study, there was substantial 
evidence found to suggest the benefit in medication assisted treatment (MAT) in patients 
suffering from opioid use disorder (Chen, 2014). Non-pharmacologic treatments such as 
counseling for mental health disorders were also found to have additive benefit in patients 
prescribed medications for depression and anxiety (Locke, 2015). Unfortunately, there are not 
enough prescribers and facilities to provide these services in many areas, especially in rural 
Nebraska. State and federal agencies should investigate innovative strategies to decrease this 
gap in care, such as condensing requirements for XDEA registration required to prescribe 
medications in MAT, promoting virtual behavioral health visits, or promoting cognitive 
behavioral therapy in primary care. State health departments can work with their opioid task 
forces and related provider groups to create patient handouts, providers tools, and CE 
programs to assist in opioid and benzodiazepine tapering and safe evidence-based treatment 
recommendations for pain and mental health disorders.  
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Study Limitations 
The results of this study were based on subjective responses rather than objective prescription 
or clinical outcomes data. Results of this study may not reflect real world changes to prescribing 
practices. Most clinicians included in this study were from Nebraska and rural areas. Future 
studies should include a greater number of clinicians from across the United States to improve 
the generalizability of these results. As noted previously, this study asked non-prescribing 
clinicians on their comfort in tapering patients on opioids and benzodiazepines, which may 
have not been appropriate. Future studies should increase the number of prescribers in their 
analysis and only ask questions applicable to each clinician’s practice.  
Conclusions 
Continuing education was associated with a statistically significant increase in self-reported 
clinician knowledge of effective alternative non-opioid and non-benzodiazepine therapies for 
chronic conditions while also increasing self-reported clinician comfort in tapering patients off 
opioid analgesics and benzodiazepines. State health departments should promote the use of CE 
in reducing perceived challenges to safely treating patients co-prescribed opioid analgesics and 
benzodiazepines in their efforts to decrease the incidence of opioid-related overdose.  
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Service Learning/Capstone Experience Reflection 
 The Nebraska Department of Health and Human Services consists of several different 
divisions. During my Service Learning experience, I worked specifically with individuals within 
the division of Public Health. This division has several responsibilities, such as regulation and 
licensure of health professionals and healthcare facilities, and various community health 
programs and services. During my on-site visit, I had the opportunity to discuss several ongoing 
projects, such as the Pain Guidance document, the new Prescription Drug Monitoring Program 
(PDMP), and the drug overdose prevention efforts involving naloxone. I learned that the 
department works heavily with stakeholders in the community, such as the Nebraska Medical 
Association and various physicians and pharmacists. The department was also in tune with 
pending legislative bills with the potential of significantly impacting their work. Throughout the 
Service Learning and Capstone experience, we utilized their network of subject matter experts 
while leveraging pending legislation to facilitate the success of our initiatives.     
 In October of 2017, I began working with the NeDHHS after connecting with Amy 
Reynoldson. Through communication over email and phone, we discussed the requirements of 
the Service Learning and Capstone project, as well as ongoing applicable projects at the division 
of public health. During my visit at the NeDHHS in Lincoln, I narrowed the focus of my project to 
the new Nebraska Pain Guidance document and its recommendation to discourage 
concomitant opioid and benzodiazepine use. Amy introduced me to Dale Mahlman, the 
Executive Vice President of the Nebraska Medical Association (NMA). In January of 2018, I had 
the opportunity to meet Dale in person at the NMA and discuss how we would incorporate the 
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capabilities and network of the NMA into discouraging the co-prescribing of opioids and 
benzodiazepines among Nebraska physicians.  
 After deciding on an appropriate topic for the Service Learning and Capstone project, I 
met with Dr. Nizar Wehbi at UNMC to discuss the course requirements while narrowing the 
scope of the projects so that they were measurable and achievable within the timeframe of the 
course. After meeting with Dr. Wehbi, I began to put together the project proposal and worked 
with Amy to ensure that the NeDHHS and NMA could accommodate our vision. We decided 
that I would create a CE presentation accredited by the NMA targeted towards Nebraska 
physicians. We discussed the importance of conducting a needs assessment survey prior to the 
CE presentation to ensure that we were providing education that was applicable to Nebraska 
physicians. This survey would assess the specific challenges that Nebraska physicians face that 
allow the concomitant use of opioids and benzodiazepine therapies to persist. After a literature 
review of previous surveys in the United States, a draft of the needs assessment was created 
and reviewed with Amy. In February, I met with Dale Mahlman and Dr. John Massey, the Task 
Force Chair of the NeDHHS Pain Guidance Document, to discuss the project and needs 
assessment survey. In March, I was invited back to the NMA to share the needs assessment 
with the Pain Management Task Force during their scheduled evening meeting to solicit 
additional feedback. After incorporating their recommendations into the need’s assessment, a 
project proposal meeting was held with Dr. Wehbi and Amy at UNMC to solidify expectations 
for the Service Learning and Capstone course. The project proposal was approved after 
receiving confirmation from Gail Kotulak, an IRB Administrator at UNMC, that the project would 
not require IRB approval.  
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 I had the opportunity to meet several other providers from a variety of healthcare 
settings to receive additional feedback on the needs assessment survey. In April, I met with Dr. 
Thomas Tape, Chief of the UNMC Division of General Internal Medicine, and Dr. Ann Polich, 
Vice President of Quality and Performance Improvement at Methodist Health System, to 
discuss the needs assessment survey while receiving their unique perspectives on opioid 
treatment. Afterwards, I met with Jeff Huether and Clint Williams at Blue Cross Blue Shield of 
Nebraska to discuss initiatives that local health plans were taking to address the opioid 
epidemic. After receiving feedback from multiple stakeholders, it was decided that the most 
efficient way of sending the needs assessment survey would be through an electronic platform 
via email. After researching several different survey platforms, we decided to utilize Google 
forms for our needs assessment.  
 In the summer of 2018, Amy took on a new position as the new Executive Vice President 
of the NMA ahead of Dale Mahlman’s retirement in January 2019. I was fortunate enough to 
have Ashley Newmyer, Deputy Director at the NeDHHS Division of Public Health, step in as the 
new preceptor for my Capstone project. After receiving additional feedback from Jeff Armitage 
at the NeDHHS on my survey, I reconciled all stakeholder input to create the final needs 
assessment survey with Google forms. The final survey included 15 total questions formatted 
using a 5-item Likert scale while allowing free responses after certain sections (see Appendix A). 
The goal of the survey was to find the challenges that providers face when treating patients on 
concomitant opioid and benzodiazepine therapies. The survey also sought feedback on 
potential objectives for a future CE presentation. With the assistance of Amy, the survey was 
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emailed to Nebraska Physicians registered with the NMA. A summary of the 79 responses 
received is included in Appendix B.  
 As I was receiving responses to the needs assessment survey, I began to put together 
the CE presentation. With Amy’s assistance, I had the opportunity to coordinate with the Great 
Plains Quality Innovation Network (GPQIN) to create the final objectives of the CE webinar and 
provide information required for an email advertisement. The CE presentation was accredited 
by the NMA while final walkthrough and presentation dates were scheduled. To broaden the 
audience of the survey, we decided to invite all types of clinicians (e.g., nursing, pharmacists, 
providers) from any location (i.e., we would no longer limit the CE presentation to Nebraska 
physicians). I completed an extensive literature search to piece together the final CE 
presentation. The CE presentation would include recommended non-opioid and non-
benzodiazepine therapies for treating patients with pain and mental health conditions. The 
presentation also provided guidance on tapering opioids and benzodiazepines while providing 
tools on discussing these topics with patients. A final walkthrough of the presentation was 
completed virtually on March 22nd. On March 27th, I traveled to the GPQIN office in Lincoln to 
deliver the live CE webinar. The slides used for the presentation can be found in Appendix C, 
and the results of pre- and post-assessment questions can be found in Appendix D. Additional 
information on this presentation and its impact on clinician knowledge and comfort in 
treatment patients can be found in the final Capstone paper.  
 I believe my background in pharmacy significantly helped me throughout this Service 
Learning and Capstone experience.  In creating the focus for the project, I drew from my 
personal experiences and anecdotes of patients receiving unsafe combinations of opioids and 
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other depressants. My clinical background and previous experience in research allowed me to 
navigate through a large amount of literature to create an appropriate needs assessment 
survey and effective CE presentation. I also faced several challenges throughout this learning 
experience. Prior to creating the project proposal, I found it difficult to narrow the project focus 
while making sure it aligned with the requirements of the Service learning and Capstone course. 
Discussing the project with Amy and Dr. Wehbi helped me finalize the project to ensure it 
would be mutually beneficial to me and the NeDHHS while also being achievable. Additionally, 
while a few physicians were welcoming and motivated to meet and discuss the project, I found 
that the idea of traveling to meet providers to obtain in-person responses for the needs 
assessment within the timeline of my project would be extremely difficult. After discussing with 
Dr. Tape, it was recommended that I utilize email to obtain electronic responses for the needs 
assessment survey to minimize respondent time commitments. During the summer of 2018, 
several life changes occurred that made continuing the project at an effective pace difficult. I 
began a new position with my employer that included increased responsibilities and time 
commitments. During this same time, I also bought a house. These time commitments put a 
substantial strain on the project. After Amy transitioned to her new position at the NMA, it took 
some time for me to reach out to Ashely and dedicate the time necessary to complete the 
Capstone project. However, these experiences helped me improve my communication and time 
management skills. I truly believe these skills developed as a result of these challenges will help 
me long after the completion of my education.   
 During this experience, I have realized that great things are possible when individuals 
from separate areas of expertise collaborate towards a common goal. During my pharmacy 
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education, the curriculum stressed the importance of learning to work on an interprofessional 
team. This ideology came together again in a different context during this service learning and 
capstone experience. Creating connections to several individuals and organizations proved to 
be invaluable throughout this process. By interacting with experts from medicine, health 
systems, and health plans, I was able to form a well-rounded vision of the current opioid 
epidemic and the interventions being deployed to decrease the incidence of opioid overdose. I 
have also learned there are many individuals who are willing to dedicate a considerable amount 
of time to assisting with a project if it aligns with their personal or professional goals. I had a 
great experience interacting with several individuals and organizations that ultimately lead to 
the success of the needs assessment and CE webinar. Finally, I have developed project 
management skills along the way that should help me going forward.  
My public health education was crucial to the success of the Service Learning and 
Capstone experience. During the public health curriculum, I developed skills in survey 
development while learning the importance of performing a needs assessment that motivated 
my project proposal. The skills developed in Biostatistics and Applies Research in Public Health 
allowed me to choose an appropriate statistical test and interpret my results. I utilized 
ideologies from Health Behavior and theoretical models to prepare an effective CE webinar 
aimed at overcoming the stigma of opioid use and therapies such as medication-assisted 
treatments (MAT) to encourage the use of evidence-based practices. I strongly believe that the 
public health curriculum provided a foundation of skills and practices that facilitated my success 
in completing this Service Learning and Capstone project.  
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Appendices 
Appendix A. Survey to Assess Barriers and Challenges to Treating Patients Prescribed both an Opioid 
and Benzodiazepine (adapted from the Google Forms version)  
Section 1: Please answer the following demographic questions:  
1. What type of provider are you (e.g., Physician, Physician Assistant, Nurse Practitioner, etc.)? 
 
 
2. Please specify the area of medicine you would consider your specialty (e.g., Internal Medicine, 
Family Medicine, Psychiatry, Pain Management, etc.)? 
 
 
3. Which of the following best describes the area you practice most of your time in?  
a. Urban (e.g., city with greater than 50,000 people)     b. Rural (e.g., city with less than 50,000 
people) 
 
Section 2: Please select the option that best describes how often you use the following strategies when 
treating patients prescribed opioid analgesics and benzodiazepines: 
4. When tapering a patient off an opioid, I use the following strategy or strategies: 
 Never Rarely Sometimes Usually Always 
Prescribe therapies such as hydroxyzine and 
clonidine for withdrawal side effects 
     
Provide or refer to psychosocial support such 
as cognitive behavioral therapy 
     
Refer patient to pain specialty care or a 
provider specializing in pain management 
     
Refer patient to medication assisted 
treatment (MAT) 
     
 
5. When tapering a patient off a benzodiazepine, I use the following strategy or strategies: 
 Never Rarely Sometimes Usually Always 
Switch from a short-acting drug (such as 
alprazolam) to a long-acting drug (such as 
clonazepam) 
     
Prescribe therapies such as hydroxyzine and 
trazodone for withdrawal side effects 
     
Use rapid taper of benzodiazepine using 
adjuvant anti-epileptic medications such as 
valproate or carbamazepine 
     
Provide or refer to psychosocial support such 
as cognitive behavioral therapy 
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6. I use assessment tools such as the PHQ-9 (Patient Health Questionnaire for Anxiety and Depression), 
GAD-7 (General Anxiety Disorder scale), or PC-PTSD (Primary Care Screen for Post-Traumatic Stress 
Disorder) to screen patients for co-occurring mental health conditions. 
a) Never                 b. Rarely                 c. Sometimes              d. Usually                e. Always 
 
7. I use assessment tools such as the ORT (Opioid Risk Tool) or SOAPP-R (Screening and Opioid 
Assessment for Patients with Pain-Revised Screening Test) to establish a patient’s susceptibility to 
substance abuse. 
a) Never                 b. Rarely                 c. Sometimes              d. Usually                e. Always 
 
Section 3: Please select the option that best describes your level of agreement with the statement. 
8. The following are barriers to tapering patients off opioid therapies: 
 Strongly 
Disagree 
Disagree Neither 
Disagree 
or Agree 
Agree Strongly 
Agree 
There is a limited availability of effective 
alternative therapies for pain 
     
There is a lack of information on how to taper 
opioid therapies 
     
Tapering opioid therapies threaten the provider-
patient relationship 
     
There is insufficient time to taper patients off 
opioid therapies 
     
 
9. The following are barriers to tapering patients off benzodiazepine therapies: 
 Strongly 
Disagree 
Disagree Neither 
Disagree 
or Agree 
Agree Strongly 
Agree 
There is a limited availability of effective 
alternative therapies for anxiety disorders 
     
There is a lack of information on how to taper 
benzodiazepine therapies 
     
Tapering benzodiazepines threaten the 
provider-patient relationship 
     
There is insufficient time to taper patients off 
benzodiazepine therapies 
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10. The following contribute to patients remaining on concomitant opioids and benzodiazepines 
 Strongly 
Disagree 
Disagree Neither 
Disagree 
or Agree 
Agree Strongly 
Agree 
Patients appear stable on these medications 
with no adverse effects 
     
It is difficult to coordinate with other prescribers 
to taper therapies 
     
The benefits of concomitant opioids and 
benzodiazepines appear to exceed the risks 
     
Discontinuing these medications can cause 
patients to seek non-prescribed or illicit drugs 
     
 
11. Please list any additional reasons that contribute to patients remaining on concomitant opioids and 
benzodiazepines: 
__________________________________________________________________________________
__________________________________________________________________________________
__________________________________________________________________________________
_____________________________________________________________                                   ___ 
 
12. I feel equipped to treat patients with chronic pain and co-occurring substance abuse disorder.  
a. Strongly Disagree     b. Disagree      c. Neither Disagree or Agree    d. Agree   e. Strongly Agree 
 
13. I feel equipped to treat patients with chronic pain and co-occurring mental health conditions.  
a. Strongly Disagree     b. Disagree      c. Neither Disagree or Agree    d. Agree   e. Strongly Agree 
 
14. There are barriers to referring patients to:  
 Strongly 
Disagree 
Disagree Neither 
Disagree 
or Agree 
Agree Strongly 
Agree 
Medication assisted treatment (MAT) programs 
or providers specializing in addiction medicine 
     
Pain specialty care or providers specializing in 
pain management 
     
Mental health services, such as individual 
counseling and group therapy 
     
 
If you answered ‘Agree’ or ‘Strongly Agree’ to any of the statements in the previous question, please 
describe the barriers:  
__________________________________________________________________________________
__________________________________________________________________________________
__________________________________________________________________________________
_______________________________________________________________                                   ___ 
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Section 4: Please select your level of interest in listening to a presentation with Continuing Education 
(CE) credit containing the following objectives: 
 
A. Discuss the increased risk of morbidity and mortality in patients co-prescribed opioid analgesics 
and benzodiazepines 
I. Not Interested to Very Interested (5-poing Likert scale) 
 
B. Describe national and state trends in drug overdose deaths involving the combination of opioid 
analgesics and benzodiazepines 
I. Not Interested to Very Interested (5-poing Likert scale) 
 
C. Evaluate the evidence to support therapies for the treatment of anxiety, insomnia, and pain 
I. Not Interested to Very Interested (5-poing Likert scale) 
 
D. Evaluate the evidence to support strategies to taper opioid analgesics and benzodiazepines 
I. Not Interested to Very Interested (5-poing Likert scale) 
 
E. Discuss appropriate patient selection for referral to pain management, mental health services, 
medication-assisted treatment, or other specialty care 
a) Not Interested to Very Interested (5-poing Likert scale) 
 
15. What other information would you like included in a CE presentation about concomitant opioid and 
benzodiazepine use?  
__________________________________________________________________________________
__________________________________________________________________________________
__________________________________________________________________________________
_________________________________________________________________                                   _ 
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Appendix B. High level results of Survey to Assess Barriers and Challenges to Treating Patients 
Prescribed both an Opioid and Benzodiazepine (Google Forms) 
Note: Full results in attached Excel document 
Section 1: Please answer the following demographic questions 
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Section 2: Please select the option that best describes how often you use the following 
strategies when treating patients prescribed opioid analgesics and benzodiazepines 
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Section 3: Please select the option that best describes your level of agreement with the 
statement 
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Section 4: Please select your level of interest in listening to a presentation with Continuing 
Education (CE) credit containing the following objectives: 
 
44 
 
 
 
45 
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Appendix C. See attached PDF document of PowerPoint Slides. Overcoming the Challenges to Treating 
Patients on Concomitant Opioid and Benzodiazepine Therapy 
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Appendix D. Results of Pre- and Post-Webinar Responses in Study Sample 
    
I am 
knowledgeable 
of effective non-
opioid therapies 
to treat chronic 
pain   
I am 
knowledgeable of 
effective non-
benzodiazepine 
therapies to treat 
anxiety disorders   
I feel 
comfortable 
tapering my 
patients off 
opioid 
therapies   
I feel 
comfortable 
tapering my 
patients off 
benzodiazepin
e therapies   
[Going forward,] I [will] utilize 
assessment tools and Prescription 
Drug Monitoring Program (PDMP) 
data to evaluate the risk of 
medication misuse when 
prescribing opioids or 
benzodiazepines for long term use.   
Clinician 
Type State 
Urban/ 
Rural Pre Post Pre Post Pre Post Pre Post Pre Post 
nursing NE Urban 3 5 3 5 3 5 3 5 2 5 
nurse 
practitioner NE Rural 4 5 4 5 3 5 3 5 5 5 
nurse 
practitioner NE Rural 4 4 4 4 3 5 3 4 3 5 
nursing KS Urban 4 4 4 3 4 4 4 4 4 4 
pharmacist NE Urban 4 5 4 5 4 5 4 5 5 5 
nursing SD Rural 4 4 4 4 4 4 4 3 3 4 
physician 
assistant NE Rural 4 5 3 5 4 5 4 5 2 5 
nursing NE Rural 4 4 4 4 2 4 2 4 2 4 
nursing OK Urban 4 4 3 4 3 4 3 4 5 4 
nursing NJ Urban 4 5 4 5 3 5 3 5 3 5 
physician 
assistant NE Rural 5 4 2 4 5 4 5 4 3 4 
physician NE Rural 4 4 2 4 3 3 4 3 4 3 
pharmacist RI Urban 4 4 4 4 3 4 3 4 3 4 
nursing NE Urban 4 5 4 5 4 5 4 5 4 5 
nursing NE Rural 4 5 4 5 3 4 3 4 5 4 
other NE Urban 3 4 3 4 3 3 3 3 3 4 
nursing KS Rural 3 4 2 4 3 4 3 4 3 5 
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I am 
knowledgeable 
of effective non-
opioid therapies 
to treat chronic 
pain 
I am 
knowledgeable of 
effective non-
benzodiazepine 
therapies to treat 
anxiety disorders 
I feel 
comfortable 
tapering my 
patients off 
opioid 
therapies 
I feel 
comfortable 
tapering my 
patients off 
benzodiazepin
e therapies 
[Going forward,] I [will] utilize 
assessment tools and Prescription 
Drug Monitoring Program (PDMP) 
data to evaluate the risk of 
medication misuse when 
prescribing opioids or 
benzodiazepines for long term use. 
Clinician 
Type State 
Urban/ 
Rural Pre Post Pre Post Pre Post Pre Post Pre Post 
nursing IL Urban 3 4 2 4 1 4 1 4 3 5 
physician NE Urban 4 4 3 4 4 3 3 3 4 4 
nurse 
practitioner NE Rural 4 4 4 4 4 5 4 5 2 5 
pharmacist NE Rural 4 4 4 4 3 3 3 3 4 5 
nursing NE Rural 4 3 4 3 4 2 4 2 3 3 
physician 
assistant NE Rural 5 4 5 4 5 3 5 3 5 4 
pharmacist NE Rural 4 4 4 4 3 4 3 4 4 4 
physician NE Rural 3 4 3 4 3 4 3 4 3 5 
other RI Urban 5 4 5 4 5 3 5 4 5 5 
physician NE Rural 4 4 3 4 3 4 3 4 3 4 
pharmacist NE Rural 4 5 4 5 3 5 3 5 3 5 
physician 
assistant NE Rural 4 5 2 5 4 5 4 5 4 5 
nursing NE Rural 4 4 4 4 3 4 2 4 3 4 
physician NE Rural 5 5 5 5 5 5 5 5 5 3 
*1 = Strongly Disagree; 2 = Disagree; 3 = Neither Agree or Disagree; 4 = Agree; 5 = Strongly Agree 
 
 
